ATAI - Leadership updates

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it before. Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage company developing novel treatments for depression and anxiety, has just brought in exactly that kind of operator, appointing Michael Halstead, the former President of Intra-Cellular Therapies, as Chief Executive Officer, effective immediately. The move lands months before the company's first pivotal Phase 3 data readout, and it places Helus alongside a cohort of companies working to modernize psychiatric treatmen

AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitutionThe Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarkedInclusion expands AtaiBeckley’s visibility across U.S. equity markets following recent additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026 NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be ad

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off

Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp

SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc

- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - - His deal sheet includes transactions totaling more than USD 2.7 billion in CNS and beyond - NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) --  atai Life Sciences N.V., (NASDAQ:ATAI) ("atai" or the "Company"), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Company's Chief Busines

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Kures Therapeutics, Inc ("Kures"), an atai Life Sciences N.V. (NASDAQ:ATAI) ("atai") company focused on developing treatment options to better manage addictions, depression, and pain, today announced the appointment of Chad E. Beyer, Ph.D., MBA, currently Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc ("Promentis"), as Chief Executive Officer of Kures, effective July 1, 2022. Dr. Beyer has over 25 years of experience in the discovery, research and translational development of medications that treat the central nervous system and neurological disorders. He has led several preclinical and clinical drug discove